Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacodynamic Effects of Cotadutide (MEDI0382) in Obese Subjects With NAFLD/NASH
NCT04019561Phase 2Completed
- Sponsor
- MedImmune
- Start
- Sep 2019
- Primary completion
- May 2021
- Modality
- Peptides
- Countries
- 2
01
Overview
A Phase 2 trial of cotadutide in non-alcoholic fatty liver disease (NAFLD), Nonalcoholic steatohepatitis (NASH), sponsored by MedImmune. Started Sep 2019; status: completed.
02
Drugs
cotadutide
03
Conditions
non-alcoholic fatty liver disease (NAFLD)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04019561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04019561.